Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Homoharringtonine + BCL-2 inhibitor + rituximab + prednisone in relapsed/refractory DLBCL (Phase Ib/II, single-arm)
ChiCTR2500107690Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of homoharringtonine, rituximab and prednisone in diffuse large B-cell lymphoma (DLBCL), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: Overall response rate, Dose-limiting toxicities (DLT) and 2 more. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
homoharringtoninerituximabprednisone
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2500107690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107690.